34results about "Growth hormones" patented technology

The invention belongs to the technical field of biological medicines, and discloses a novel long-acting recombinant human growth hormone fusion protein. The fusion protein is obtained by fusion expression of human growth hormone (hGH) and an anti-human albumin nano antibody (VHH). And the long-acting principle is that the clearance rate is reduced by reversibly and widely combining with albumin with endogenous circulation. The fusion protein has the characteristics that 1, the fusion protein is obtained by fusion expression of two functional domains of hGH and VHH, hGH sequence mutation and complex chemical modification are not involved, the preparation method is simpler, and the sample uniformity is better; 2, in the fusion protein, the N end of the hGH protein has no additional structure, and the VHH functional domain is connected to the C end of the hGH, so that the influence on the activity of the hGH is reduced; and 3, animal efficacy results show that the fusion protein has a long-acting effect.

To provide nucleic acids (including AAV expression cassettes), AAV vectors, and compositions for use in methods of treating and / or delaying the onset of diseases associated with mutations in mecp2 genes, such as Rett Syndrome.SOLUTION: Also provided herein are methods for treating a brain-derived neurotrophic factor (BDNF) - associated disease and / or delaying the onset of a brain-derived neurotrophic factor (BDNF) - associated disease. The present disclosure provides a nucleic acid comprising an adeno-associated virus (AAV) expression cassette, wherein the AAV expression cassette comprises, in a 5' to 3' direction, a 5' inverted terminal repeat (ITR), a synthetic activity-dependent promoter, a Rett syndrome-associated gene, and a 3' ITR.SELECTED DRAWING: None

A linker for linking a therapeutic agent to another moiety, such as the Fc region of an antibody. A linker having two or more maleimide functional groups capable of undergoing a nucleophilic conjugate addition reaction. A method for increasing the duration of action of a therapeutic agent by conjugating it to a novel linker and the Fc region of an antibody. An antibody-drug conjugate having an increased duration of action over the drug alone.

This disclosure provides engineered aminoacyl tRNA synthetases and tRNAs for efficient production of proteins containing non-standard amino acids. These engineered orthogonal tRNA (O-tRNA) / orthogonal aminoacyl tRNA synthetase (O-RS) pairs, i.e., Orthogonal Translation Systems (OTSs) can be used to incorporate a non-standard amino acid in a specific position in a growing polypeptide in response to a selector codon that is recognized by the engineered tRNA.

The present invention relates to a solid oral pharmaceutical composition comprising (i) a core comprising a peptide or protein drug, and (ii) a first coating, wherein the first coating comprises a copolymer (A) in combination with a copolymer (B) and / or a copolymer (C) and / or a copolymer (D).

The present invention relates to the fields of biotechnology and aquaculture, and in particular to a method for increasing the growth rate of fishes. The method comprises the following steps: fusing a coding region of a gh1 gene with a strong promoter of another endogenous highly-expressed gene in vivo, without introducing an exogenous gene, to generate a gh1 highly-expressed gene, wherein the strong promoter is a β-actin gene promoter. The present invention can create fast-growing fish species.

This application relates to the fields of biotechnology, immunology, virology, genetics, and molecular biology. More specifically, the present invention relates to an isolated recombinant receptor-binding domain (RBD-S) of the S glycoprotein of SARS-CoV-2 (severe acute respiratory syndrome-associated coronavirus 2), a nucleic acid encoding the RBD-S of SARS-CoV-2, expression cassettes and vectors based thereon, and a recombinant AAV5 (adeno-associated virus serotype 5)-based virus for inducing SARS-CoV-2-specific immunity and / or preventing SARS-CoV-2-related coronavirus infection, an AAV5-based vaccine for inducing SARS-CoV-2-specific immunity and / or preventing SARS-CoV-2-related coronavirus infection, and uses thereof for inducing SARS-CoV-2-specific immunity and / or preventing SARS-CoV-2-related coronavirus infection.

To provide a long-acting growth hormone that demonstrates efficacy outcomes superior to daily somatropin.SOLUTION: The present invention provides a long-acting growth hormone or a pharmaceutical formulation comprising such a long-acting growth hormone for use in a method of reducing the percentage of non-responding individuals in a patient population suffering from growth hormone deficiency.SELECTED DRAWING: None

The invention belongs to the technical field of biological medicine and nano-drug delivery, and particularly relates to a long-acting growth hormone (hGH) wrapped bacterial outer membrane vesicle and application, and the outer membrane vesicle GH-OMVs wraps a human growth hormone mutant with an amino acid sequence shown as SEQ ID NO: 1. The GH-OMVs provided by the invention can be used for preparing medicines or preparations for preventing and / or treating diseases related to growth hormone deficiency or growth hormone-related metabolic disorder, including but not limited to growth hormone deficiency, dwarf / low height, osteoporosis and the like, and has a good clinical application prospect.

The present application relates to a kind of Fc mutant, fusion protein, nucleic acid molecule, expression vector, recombinant cell, pharmaceutical composition and its purposes.Fc mutant has the amino acid sequence as any one of SEQ ID NO:3~7;Fusion protein includes: second peptide segment, second peptide segment is the functional region of bioactive molecule, third peptide segment, third peptide segment includes the amino acid sequence shown in SEQ ID NO:2 or the Fc mutant of preceding, second peptide segment is connected with third peptide segment.The Fc mutant of the present application is monomer form, fusion protein has higher in vitro and in vivo activity and lower ADCC, CDC effect, can effectively treat growth hormone deficiency.

The present invention provides a sustained-release formulation of human growth hormone that can be administered at high concentrations and in injection volumes of less than 1.0 mL for a variety of indications requiring human growth hormone therapy. The present invention relates to human growth hormone polymer prodrugs, as well as dry, liquid and reconstituted pharmaceutical formulations comprising said prodrugs. The invention further relates to their use as medicaments for treating diseases treatable by growth hormone, and to methods of treatment. The invention also relates to methods of administering such human growth hormone polymer prodrugs or pharmaceutical formulations.

A composition for use in treating a coagulation or clotting disorder, treating excessive bleeding or bruising, or maintaining homeostasis following a mild to moderate bleed in a subject, the composition comprising a human chorionic gonadotropin carboxy terminal peptide (CTP)-modified human active Factor VII (FVIIa) polypeptide comprising three CTP molecules attached in tandem to the C-terminal end of FVIIa and having the amino acid sequence of SEQ ID NO: 7, wherein the CTP-modified FVIIa polypeptide is in a substantially pure and active form, the CTP-modified FVIIa polypeptide having a high sialic acid content of at least 15 mol / mol

The invention belongs to the technical field of animal genetic engineering, and particularly relates to a method for increasing the growth speed of pigs. The method comprises the following steps that under the condition that an exogenous gene is not introduced, a coding region of a GH1 gene and a strong promoter of another endogenous high-expression gene are fused in vivo, the GH1 high-expression gene is generated, and the strong promoter is a PSMC5 gene promoter, an ACTA1 gene promoter, an ACTB gene promoter, an NME2 gene promoter or an RPL23 gene promoter. According to the method, pig varieties which grow rapidly can be created.

The invention discloses an affinity chromatography method for purifying human growth hormone and a DARPin dimer ligand. The DARPin dimer comprises a first DARPin monomer and a second DARPin monomer which are connected through a connecting peptide or a disulfide bond; each DARPin monomer is provided with a four-section type structure of an N-cap, a first internal repeated module IR1, a second internal repeated module IR2 and a C-cap; the amino acid sequence of the DARPin monomer is selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5 in a sequence list, and the amino acid sequence of the DARPin monomer has 90%-98% sequence identity with any amino acid sequence selected from the list. According to the present invention, through the design of the DARPin dimer ligand having the N-cap, the first internal repeating module IR1, the second internal repeating module IR2 and the C-cap four-segment structure, and the directed random mutation of the IR1 / IR2 region, the novel ligand having high affinity and high specificity on the human growth hormone is obtained, and the non-specific binding of the host protein and the structure-similar impurities is significantly reduced;

The invention relates to a long-acting growth hormone receptor antagonist comprising a growth hormone variant and an albumin binding moiety. Further described are methods of preparing said compound and use thereof in medicine e.g., for the treatment of acromegaly.

A combination of medications and medication doses is disclosed whereby age-related changes in systemic inflammation, cancer risk, heart disease risk, CD38 expression, hair color, thymotrophic hormones, immune cell populations, the CD4 / CD8 cell ratio, bone marrow density, thymus structure, kidney function, and epigenetic age can be reversed in humans. Surprisingly, agents that accelerate the growth of cells reduce cancer risk, agents that intensify immune responses attenuate age-related inflammation, agents with no prior connection to hair color reverse age-related hair whitening, and a combination of agents that induces IGF-1, a hormone previously thought to drive systemic aging, results in a reversal of systemic aging as documented by an epigenetic clock. Medication combinations useful in the present invention include human growth hormone (GH) or GH releasers, dehydroepiandrosterone (DHEA), and metformin.

The invention belongs to the field of biotechnology and aquaculture, and particularly relates to a method for increasing the growth speed of fishes. The method comprises the following steps that under the condition that an exogenous gene is not introduced, a coding region of a gh1 gene and a strong promoter of another endogenous high-expression gene are fused in vivo, the gh1 high-expression gene is generated, and the strong promoter is a beta-actin gene promoter. Fish varieties which grow rapidly can be created.

Described herein are growth hormone receptor antagonists and modified growth hormone receptor antagonists. The growth hormone receptor antagonists and the modified growth hormone receptor antagonists are useful in the treatment of diseases or conditions responsive to human growth hormone receptor antagonists, such as cancer and acra hypertrophy.

Provided herein at least in part are sequences and constructs that can be used for gene therapy that can avoid or reduce interaction with said intracellular DNA-binding proteins and can enhance the potency, safety, efficiency, and / or effectiveness of gene therapy treatments, as well as related compositions and methods.

The present disclosure provides a carrier protein for improving properties of a bioactive protein. The carrier protein has a G-X-Y ternary repetitive structure, G is glycine, and X and Y are independently selected from proline, alanine and glutamic acid. The present disclosure further provides a fusion protein containing the carrier protein and the bioactive protein. The fusion protein of the present disclosure has improved biological properties, such as improved pharmacokinetic and physicochemical properties.

Provided herein at least in part are sequences and constructs that can be used for gene therapy that can avoid or reduce interaction with said intracellular DNA-binding proteins and can enhance the potency, safety, efficiency, and / or effectiveness of gene therapy treatments, as well as related compositions and methods.

The present invention relates to a method for differentiating induced pluripotent stem cells into retinal pigment epithelial cells. Furthermore, the present invention relates to a retinal pigment epithelial cell culture obtainable by the differentiation method and a retinal pigment epithelial cell culture obtained by the differentiation method. Furthermore, the present invention relates to a retinal pigment epithelium consisting of or comprising a retinal pigment epithelial cell culture obtainable or obtained by the differentiation method. The present invention also relates to a pharmaceutical composition comprising a retinal pigment epithelial cell culture obtained by the differentiation method. The present invention also relates to a method for treating a retinal degenerative disease in a subject, comprising administering to the subject retinal pigment epithelial cells differentiated from induced pluripotent stem cells by the method. Finally, the present invention also relates to an in vivo method for detecting the viability of retinal pigment epithelial cells differentiated from induced pluripotent stem cells by the defined method in a subject, and an in vitro method for determining the immunogenicity of the retinal pigment epithelial cells differentiated from induced pluripotent stem cells by the defined method in the subject to which the differentiated RPE cells have been previously delivered. TIFF2025507265000008.tif19278

The present application discloses compositions and methods for use of nucleoside modified mRNA that encode for at least one liver regenerative factor. The present invention also relates to compositions and methods for use of nucleoside modified mRNA complexed to nanoparticles. The disclosed compositions and methods are useful for treating acute liver diseases, chronic liver diseases, and / or acetaminophen (acetyl-para-aminophenol, APAP) overdose.

The present invention relates to long-acting growth hormone receptor antagonists comprising a growth hormone variant and an albumin-binding moiety. Methods for preparing and using the compounds in pharmaceuticals, for example, for the treatment of acromegaly, are further described.

This invention discloses a method for preparing inclusion bodies based on dual-promoter expression plasmids and its application, belonging to the field of biotechnology. The invention includes screening of totipotent nucleases, purification of totipotent nucleases, verification of the degradation activity of the totipotent nuclease DNS on nucleic acids, construction of dual-promoter recombinant strains, fermenter culture, cell recovery, and cell disruption to obtain crude inclusion bodies. This invention achieves high-efficiency expression of the recombinant human growth hormone gene induced by the T7 promoter and high-activity expression of the totipotent nuclease gene DNS induced by the cspA promoter, demonstrating significant effects in the application of recombinant human growth hormone. During the preparation process, the cell viscosity is low, the homogenization and disruption effect is improved, the BL21(DE3) / DGH cell disruption rate is high, the inclusion body content harvested by centrifugation per unit volume of fermentation broth is high, and the residual amount of HCD (host DNA residue) in the target protein per unit mass is reduced, effectively reducing energy consumption.

The present invention relates to an extruded depot for sustained release of an active agent comprising at least one active agent and at least one first compound from the class of biodegradable organic polymers based on lactic acid and / or glycolic acid.

The present invention provides a method for purification of a recombinant protein, in particular to a recombinant human albumin; the method includes: (a) adding aminoguanidine and a medium-long chain fatty acid to a sample containing the recombinant protein; and (b) chromatographing the obtained sample, where the chromatography is optionally performed with a chromatographic buffer solution containing aminoguanidine.

The present disclosure provides antagonist fusion polypeptides (e.g., with extended half-life, improved antagonist activity) comprising (i) a serum albumin binding polypeptide; (ii) a polypeptide hormone analog capable of antagonizing its receptor activation; and (iii) a linker, as well as various related technologies including, methods of producing and using such fusion polypeptides.

The present invention belongs to the technical field of animal genetic engineering, and specifically relates to a method for improving the growth rate of pigs. The method comprises the following steps: fusing, in vivo, a coding region of a GH1 gene with a strong promoter of another endogenous high-expression gene without introducing an exogenous gene to generate a GH1 high-expression gene, wherein the strong promoter is a PSMC5 gene promoter, an ACTA1 gene promoter, an ACTB gene promoter, an NME2 gene promoter or an RPL23 gene promoter. According to the method, pig breeds with a rapid growth rate can be created.